Loading
A phase 1/2 trial of Toripalimab in advanced solid tumours, run by LaNova Medicines Limited, now recruiting.
A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours is a phase 1/2 interventional study registered as NCT06868199 by LaNova Medicines Limited, with 87 participants planned, started 2025-05-06 and due to reach its primary completion in 2027-08-01. Interventions recorded: LM-168 and Toripalimab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares LaNova Medicines, Toripalimab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares LaNova Medicines, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares LaNova Medicines, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares LaNova Medicines, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares LaNova Medicines, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Toripalimab, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares LaNova Medicines, Toripalimab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares LaNova Medicines, Toripalimab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/